QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chaki, S. Articles by Okuyama, S. Search for Related Content PubMed PubMed Citation Articles by Chaki, S. Articles by Okuyama, S.

NEUROPHARMACOLOGY

Anxiolytic-Like and Antidepressant-Like Activities of MCL0129 (1-[(S)-2-(4-Fluorophenyl)-2-(4-isopropylpiperadin-1-yl)ethyl]-4-[4-(2-methoxynaphthalen-1-yl)butyl]piperazine), a Novel and Potent Nonpeptide Antagonist of the Melanocortin-4 Receptor

Medicinal Pharmacology Laboratory (S.C., S.H., T.F., Y.S., S.S.), Medicinal Chemistry Laboratory (T.O., T.I., A.N.), Medicinal Research Laboratories, and Ethical Business Strategy Division (S.O.), Taisho Pharmaceutical Co., Saitama, Japan

We investigated the effects of a novel melanocortin-4 (MC4) receptor antagonist,1-[(S)-2-(4-fluorophenyl)-2-(4-isopropylpiperadin-1-yl)ethyl]-4-[4-(2-methoxynaphthalen-1-yl)butyl]piperazine (MCL0129) on anxiety and depression in various rodent models. MCL0129 inhibited [¹²⁵I][Nle⁴-D-Phe⁷]--melanocyte-stimulating hormone (-MSH) binding to MC4 receptor with a K_i value of 7.9 nM, without showing affinity for MC1 and MC3 receptors. MCL0129 at 1 µM had no apparent affinity for other receptors, transporters, and ion channels related to anxiety and depression except for a moderate affinity for the ₁ receptor, serotonin transporter, and ₁-adrenoceptor, which means that MCL0129 is selective for the MC4 receptor. MCL0129 attenuated the -MSH-increased cAMP formation in COS-1 cells expressing the MC4 receptor, whereas MCL0129 did not affect basal cAMP levels, thereby indicating that MCL0129 acts as an antagonist at the MC4 receptor. Swim stress markedly induced anxiogenic-like effects in both the light/dark exploration task in mice and the elevated plus-maze task in rats, and MCL0129 reversed the stress-induced anxiogenic-like effects. Under nonstress conditions, MCL0129 prolonged time spent in the light area in the light/dark exploration task and suppressed marble-burying behavior. MCL0129 shortened immobility time in the forced swim test and reduced the number of escape failures in inescapable shocks in the learned helplessness test, thus indicating an antidepressant potential. In contrast, MCL0129 had negligible effects on spontaneous locomotor activity, Rotarod performance, and hexobarbital-induced anesthesia. These observations indicate that MCL0129 is a potent and selective MC4 antagonist with anxiolytic- and antidepressant-like activities in various rodent models. MC4 receptor antagonists may prove effective for treating subjects with stress-related disorders such as depression and/or anxiety.

Address correspondence to: Dr. Shigeyuki Chaki, Psychiatric Diseases and Pain Research,, Medicinal Pharmacology Laboratory, Medicinal Research Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Saitama, Saitama 330-8530, Japan. E-mail: s.chaki{at}po.rd.taisho.co.jp

This article has been cited by other articles:

				J. A. Sebag and P. M. Hinkle Regulation of Endogenous Melanocortin-4 Receptor Expression and Signaling by Glucocorticoids Endocrinology, December 1, 2006; 147(12): 5948 - 5955. [Abstract] [Full Text] [PDF]

				S. O. Fetissov, J. Harro, M. Jaanisk, A. Jarv, I. Podar, J. Allik, I. Nilsson, P. Sakthivel, A. K. Lefvert, and T. Hokfelt Autoantibodies against neuropeptides are associated with psychological traits in eating disorders PNAS, October 11, 2005; 102(41): 14865 - 14870. [Abstract] [Full Text] [PDF]